B

Baroness Nargund (Lab)

Speaking in the House of Lords on 9 November 2026

Debate

Health Bill

Contribution

My Lords, I understand the importance of the amendments in this group and I support them. I want particularly to speak to Amendments 41 and 217, from the noble Baroness, Lady Pidgeon; Amendment 250 from the noble Baroness, Lady Finlay; and Amendment 233 from my noble friend Lady Royall. Cancer, as we all know, is one of the leading causes of death worldwide, and it has touched many, if not most, of our lives. As the noble Baroness, Lady Pidgeon, said, one in two of us will be affected by cancer in our lifetime. We know that the Government take cancer seriously. Their national cancer plan for England, and increased investment in earlier diagnosis and clinical trials, are truly to be applauded. But the core issue is about cancer research, which I have raised before in the House, and the impact—which I have not yet addressed in the House but have in a written form—of Brexit on our ability to conduct research, to attract research fellows from across the EU and to access funding. Before Brexit, the UK was the second-largest beneficiary of scientific research funding after Germany, and we have lost that. We have lost access to our research fellows: I used to have access to so many research fellows from the EU who came across and helped, and we did that similarly. I must declare an interest that I was a visiting professor in Belgium for nearly two decades. We exchanged research fellows, which helped enormously for original research, in particular with drugs and medicines research. We have now lost that. That is particularly relevant when it comes to rare cancers, and cancers that affect, in particular, ethnic-minority populations, because the patient population size is small, so it is not possible for NICE to conduct its cost-effectiveness and clinical effectiveness studies and come up with meaningful data to publish in high-powered scientific publications without international and EU collaboration. We desperately need that for cancer research, particularly for trials. Cancer Research UK is an absolute star in cancer research and one of the world’s largest independent cancer research organisations, but even it has had to establish trials in other countries—partnering, for example, with the Nordic Cancer Union—because it can be cheaper, easier, faster and more accessible to do so. This means that researchers can, potentially, understand how to treat cancer more quickly and effectively elsewhere than here on our own soil, particularly when it comes to addressing prostate cancer. The noble Baroness, Lady Finlay, mentioned the importance of collaborating with the EU. We know that the EU has moved on in some ways, particularly with targeted cancer screening in high-risk patients, which is something on which we seem to be lagging behind. I echo the call of the noble Baroness, Lady Pidgeon, in Amendment 217 for the establishment of a research and fellowship programme for international academics in cancer research, alongside appropriate visa support to enable them to come to the UK. I personally know how brilliant minds have decided to go elsewhere for their studies and research since Brexit. We are losing talent, expertise, collaboration, research staff and, potentially, treatments that could save the lives of cancer patients. I therefore ask my noble friend the Minister, who I know takes this issue really seriously, whether the Government have given consideration to the impact of what we have lost after Brexit. How can we get more EU collaboration for cancer research and cancer research funding? What steps are the Government taking to strengthen EU and international collaboration, in particular on setting up big research trials for rare cancers and cancers affecting minority populations, and on data sharing and access to academic clinical research trials and universities across the EU? What steps are being taken to expedite the pathway from research trials to MHRA, NICE and NHS funding pathways? That is urgent, particularly for certain cancers. What more can be done to make the UK an attractive and accessible place for international researchers, research trials, and academics?

More from Baroness Nargund (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.